May 13, 2024 02:55 PM EDT
R&D
Coronavirus

Sh­iono­gi miss­es pri­ma­ry end­point in Phase 3 for Covid-19 an­tivi­ral

Katherine Lewin

News Reporter

Sh­iono­gi’s once-dai­ly Covid-19 an­tivi­ral en­sitrelvir missed the pri­ma­ry end­point in a Phase 3 study, two months af­ter scor­ing full ap­proval in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times